Department of Pharmacology & Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland.
National Cancer Registry Ireland, Building 6800, Cork Airport Business Park, Kinsale Road, Cork, Ireland.
Cancer Epidemiol. 2014 Feb;38(1):79-84. doi: 10.1016/j.canep.2013.12.003. Epub 2014 Jan 4.
Preclinical evidence suggests a role for metformin in inhibiting tumour dissemination and metastasis. Previous studies have identified associations between metformin exposure and improved colorectal cancer survival. This study aimed to examine associations between metformin exposure and the odds of presenting with disseminated disease among colorectal cancer patients.
Colorectal cancer patients diagnosed 2001-2006 were identified from the National Cancer Registry Ireland. A linked national pharmacy claims database was used to determine exposure to anti-diabetic medications prior to diagnosis. Multivariate logistic regression was used to estimate odds ratios (OR) with 95% confidence intervals (CI) for associations between metformin use (versus non-metformin anti-diabetic drugs) and odds of presenting with disseminated disease (lymph node positive/metastatic). Analyses were stratified by anti-diabetic drug co-prescription and intensity of metformin exposure.
The study population included 241 metformin-exposed diabetics, 129 non-metformin-exposed diabetics, and 4277 non-diabetic patients. In multivariate analysis, odds of disseminated disease were lower in metformin-exposed diabetics, compared with non-metformin-exposed diabetics, though not statistically significant (OR=0.66, 95% CI 0.39-1.12). In analyses stratified by metformin dosing intensity and anti-diabetic drug co-prescription, the odds were further from unity and approached significance in diabetics with high intensity, exclusive metformin use (OR=0.52, 95% CI 0.25-1.10).
While overall there was no statistically significant association between metformin exposure and disseminated colorectal cancer at diagnosis, there was a suggestion that high intensity, exclusive metformin use may be associated with reduced odds of disseminated disease. The number of patients in these subgroup analyses was small, and further investigation in larger studies is warranted.
临床前证据表明二甲双胍在抑制肿瘤扩散和转移方面具有作用。先前的研究已经确定了二甲双胍暴露与改善结直肠癌生存之间的关联。本研究旨在研究二甲双胍暴露与结直肠癌患者出现播散性疾病的几率之间的关联。
从爱尔兰国家癌症登记处确定了 2001-2006 年诊断的结直肠癌患者。使用链接的国家药房索赔数据库来确定诊断前抗糖尿病药物的暴露情况。使用多变量逻辑回归来估计二甲双胍使用(与非二甲双胍抗糖尿病药物相比)与出现播散性疾病(淋巴结阳性/转移性)的几率之间的比值比(OR),并带有 95%置信区间(CI)。分析按抗糖尿病药物联合处方和二甲双胍暴露强度进行分层。
研究人群包括 241 名二甲双胍暴露的糖尿病患者、129 名非二甲双胍暴露的糖尿病患者和 4277 名非糖尿病患者。在多变量分析中,与非二甲双胍暴露的糖尿病患者相比,二甲双胍暴露的糖尿病患者出现播散性疾病的几率较低,但无统计学意义(OR=0.66,95%CI 0.39-1.12)。在按二甲双胍剂量强度和抗糖尿病药物联合处方分层的分析中,在高强度、独家使用二甲双胍的糖尿病患者中,几率进一步偏离 unity 并接近显著性(OR=0.52,95%CI 0.25-1.10)。
虽然总体而言,二甲双胍暴露与诊断时结直肠癌的播散之间没有统计学上的显著关联,但有迹象表明,高强度、独家使用二甲双胍可能与降低播散性疾病的几率有关。这些亚组分析中的患者数量较少,需要在更大的研究中进一步调查。